Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009:542:705-17.
doi: 10.1007/978-1-59745-561-9_35.

Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas

Mateusz Opyrchal  1 , Ileana Aderca, Evanthia Galanis
Affiliations
Clinical Trial

Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas

Mateusz Opyrchal et al. Methods Mol Biol. 2009.

Abstract

Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There is an need for more efficient and less toxic treatments in this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(a,b) Focal areas of viral replication were demonstrated by in situ hybridization in the tumor of one of the study patients, (c,d) Close-up view of the positive areas. (Reproduced from (21) with permission),
See this image and copyright information in PMC

References

    1. Baker IC, Smale ST, Tjian R, Ames BN. Inhibition of simian virus 40 DNA replication in vitro by poly(ADP-ribosyl) ated diadenosine tetraphosphate. J Biol Chem. 1947;262:14955–8. - PubMed
    1. Dobner T, Horikoshi N, Rubenwolf S, Shenk T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science. 1996;272:1470–3. - PubMed
    1. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature. 1992;357:82–5. - PubMed
    1. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattacy A, McCormick F. An adenovirus mutant that replicates selectively in p53, dcficicnt human tumor cells. Science. 1996;274:373–6. - PubMed
    1. Turnell AS, Grand RJ, Gallimore PH. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol. 1999;73:2074–83. - PMC - PubMed

Publication types